Terminated PHASE2 INTERVENTIONAL 1-arm NCT00746590

Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma

A Phase 2 Study of the Anti-tumour Activity and Safety of Prolarix™ in Hepatocellular Carcinoma (HCC)

Sponsor: BTG International Inc.

Interventions Prolarix (tretazicar co-administered with caricotamide)

Updated 8 times since 2017 Last updated: Jul 13, 2022 Started: Sep 30, 2008 Primary completion: Jun 30, 2009 Completion: Aug 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study terminated prematurely by sponsor for business reason. One patient was enrolled.

Other terminated trials from BTG International Inc.

More terminations from BTG International Inc.

Other Hepatocellular Carcinoma trials with similar outcome

Browse all Hepatocellular Carcinoma trials

A PHASE2 clinical study on Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by BTG International Inc. and has accumulated 8 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Sep 2022 — Jul 2024 [monthly]

Terminated PHASE2
Jul 2022 — Sep 2022 [monthly]

Terminated PHASE2
Mar 2022 — Jul 2022 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jan 2021 — Mar 2022 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

BTG International Inc.

Data source: BTG International Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Brussels, Belgium